Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.

[1]  Y. Iwamoto,et al.  Involvement of P‐glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug‐resistant osteosarcoma and Ewing's sarcoma cells , 2006, International journal of cancer.

[2]  R. Samulski,et al.  Adeno-associated virus vectors: potential applications for cancer gene therapy , 2005, Cancer Gene Therapy.

[3]  S. Kohno,et al.  Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. , 2005, Lung cancer.

[4]  Roman Rouzier,et al.  Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma , 2005, Cancer.

[5]  M. J. Newman,et al.  A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer , 2005, Investigational New Drugs.

[6]  D. Piwnica-Worms,et al.  In vivo RNA Interference–Mediated Ablation of MDR1 P-Glycoprotein , 2005, Clinical Cancer Research.

[7]  Francisco Gamarro,et al.  Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. , 2005, Cancer research.

[8]  S. Cole,et al.  Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. , 2005, Toxicology and applied pharmacology.

[9]  R. Samulski,et al.  Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  M. Izquierdo.  Short interfering RNAs as a tool for cancer gene therapy , 2005, Cancer Gene Therapy.

[11]  M. Morris,et al.  FLAVONOIDS CHRYSIN AND BENZOFLAVONE, POTENT BREAST CANCER RESISTANCE PROTEIN INHIBITORS, HAVE NO SIGNIFICANT EFFECT ON TOPOTECAN PHARMACOKINETICS IN RATS OR MDR1A/1B (–/–) MICE , 2005, Drug Metabolism and Disposition.

[12]  Michael J. Welch,et al.  Imaging Multidrug Resistance P-glycoprotein Transport Function Using MicroPET with Technetium-94m-Sestamibi , 2005, Molecular imaging.

[13]  A. Oza,et al.  Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours , 2005, Cancer Chemotherapy and Pharmacology.

[14]  S. Chong,et al.  P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats , 2005, Cancer Chemotherapy and Pharmacology.

[15]  W. T. Beck,et al.  Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. , 2004, Molecular cancer therapeutics.

[16]  J. Rader,et al.  Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies , 2004, Clinical Cancer Research.

[17]  Mariël Brok,et al.  Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. , 2004, Blood.

[18]  J. Schellens,et al.  Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice , 2004, Investigational New Drugs.

[19]  S. Steinberg,et al.  A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[20]  S. Raguz,et al.  Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1 , 2004, Gene Therapy.

[21]  C. Slapak,et al.  A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy , 2004, Clinical Cancer Research.

[22]  R. Callaghan,et al.  Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. , 2004, European journal of cancer.

[23]  S. Bates,et al.  Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.

[24]  H. Minderman,et al.  Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023 , 2004, Cancer Chemotherapy and Pharmacology.

[25]  R. Callaghan,et al.  The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models , 2003, British Journal of Cancer.

[26]  A. Harris,et al.  A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). , 2003, British journal of clinical pharmacology.

[27]  C. Ramachandran,et al.  Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts. , 2003, Anticancer research.

[28]  T. Fojo,et al.  Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Varun Garg,et al.  Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  P. Choyke,et al.  A Phase I study of infusional vinblastine in combination with the p‐glycoprotein antagonist PSC 833 (valspodar) , 2001, Cancer.

[31]  P. Choyke,et al.  Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Charlton,et al.  In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. , 2001, Cancer research.

[33]  M. J. Newman,et al.  Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. , 2000, Cancer research.

[34]  D. Stuart,et al.  A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1 , 2000, Cancer Gene Therapy.

[35]  J. Hescheler,et al.  Redox regulation of P‐glycoprotein‐mediated multidrug resistance in multicellular prostate tumor spheroids , 2000, International journal of cancer.

[36]  S. Binkley,et al.  Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. , 1999, The Journal of pharmacology and experimental therapeutics.

[37]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[38]  J. Holland,et al.  Reversal of multidrug resistance by a liposome-MDR1 ribozyme complex , 1998, Cancer Chemotherapy and Pharmacology.

[39]  D. Hipfner,et al.  Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. , 1997, Molecular pharmacology.

[40]  A. Dantzig,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. , 1996, Cancer research.